Aspira Pathlab & Diagnostics Limited has intimated BSE Limited about an upcoming meeting of its Board of Directors.
The Board Meeting is scheduled to be held on Saturday, September 12, 2026.
The primary agenda for the meeting is to consider, evaluate, and if deemed fit, approve a proposal for raising funds. The fundraising may be conducted through the issuance of one or more instruments including:
- Equity shares
- Warrants convertible into equity shares
The company may utilize various methods for this fundraising, either individually or in combination, including:
- Preferential issue
- Private placements
- Rights issue
- Any other methods permitted under the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 as amended
Any approved fundraising proposal will be subject to obtaining requisite approvals, including shareholder approval and statutory approvals.
The Board will also transact other incidental and ancillary matters as may be decided during the meeting.
The notice of this Board Meeting will be uploaded on the Company's website www.aspiradiagnostics.com as required under regulation 46(2)(l)(i) of the SEBI Listing Regulations.